Goldman Sachs
MBRX icon

Goldman Sachs’s Moleculin Biotech MBRX Stock Holding History

Goldman Sachs’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-510
Closed -$6.76K – 6674
2025
Q3 		$6.76K Buy
+510
New +$6.89K ﹤0.01% 6267
2022
Q1 		– Sell
-32
Closed -$22K – 6768
2021
Q4 		$22K Buy
+32
New +$28.4K ﹤0.01% 6359
2021
Q3 		– Sell
-69
Closed -$94K – 6398
2021
Q2 		$94K Buy
+69
New +$94.2K ﹤0.01% 5960
2017
Q2 		– Sell
-8
Closed -$20K – 6873
2017
Q1 		$20K Buy
+8
New +$28K ﹤0.01% 6515

Other funds holding MBRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Goldman Sachs's MBRX Position: Q4 2025 in Review

Goldman Sachs sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 510 shares — an estimated $6.76K sold.

Goldman Sachs first reported a position in MBRX in Q1 2017 and held it in 4 quarters. The position peaked at $94K in Q2 2021. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

  • Goldman Sachs reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
  • Goldman Sachs sold 510 Moleculin Biotech shares in Q4 2025, an estimated $6.76K.
  • Goldman Sachs first reported a position in Moleculin Biotech in Q1 2017 and held it in 4 quarters.
  • Goldman Sachs's Moleculin Biotech position peaked at $94K in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.